NovalGen
PrivateLast Round
VC Round
Nov 26, 2024
Total Funding Raised
$730,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NovalGen operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a VC Round in November 2024.
NovalGen is a biotechnology company that develops multi-specific antibody therapies and an AutoRegulation (AR) platform for the treatment of cancer, autoimmune, and other immunological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NovalGen Comparables
Compare NovalGen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lava Therapeutics | 86% | |
| Revitope Oncology, Inc. | 85% | |
| Clasp Therapeutics | 85% |
For institutional investors. Book with your work email.
NovalGen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 26, 2024 | ||||
| Grant | May 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NovalGen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCL Business | VC Round, Series A |
| Albion Capital | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 75% MoM, reaching 1K.
- Apr 18, 2026
Monthly visitors grew 525% MoM, reaching 1.7K.
For institutional investors. Book with your work email.
NovalGen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NovalGen's valuation, stock price, and market status.
Is NovalGen a public or private company?
NovalGen is a private company.
What is the current stock price of NovalGen?
NovalGen is a private company, so its shares have no public market price. Caplight tracks NovalGen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NovalGen worth (valuation)?
Valuation information for NovalGen is not publicly available.
Can I buy NovalGen stock?
NovalGen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NovalGen's last funding round?
NovalGen's most recent funding round was VC Round on November 26, 2024.
Who are the main investors in NovalGen?
Key investors in NovalGen include UCL Business, Albion Capital.
Will NovalGen IPO soon?
No public IPO plans have been announced for NovalGen.
How can I track NovalGen secondary market activity?
Caplight tracks bids, offers, and trades in NovalGen's shares on secondary markets.